Phase 2 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older (male or female)
- People who have long-term, ongoing ACTH-dependent Cushing's syndrome (a hormonal condition where the body produces too much cortisol due to excess ACTH hormone)
- People whose Cushing's syndrome has been actively causing symptoms within 10 days before the first study visit
- People currently taking certain medications for Cushing's syndrome (ketoconazole, levoketoconazole, osilodrostat, or metyrapone) may be considered, provided those medications are stopped for at least 5 days before joining, and the treating doctor agrees this is appropriate
- People currently taking cabergoline for Cushing's syndrome may be considered, provided that medication is stopped for at least 14 days before joining, and the treating doctor agrees this is appropriate
Who may not be able to join:
- Women who are pregnant or currently breastfeeding
- People who have had both adrenal glands surgically removed
- People whose previous brain scans have shown an ACTH-producing growth located very close (within 3 mm) to the optic chiasm, which is a nerve structure near the brain (confirm with trial site)
- People who have any known cancer diagnosis
- People currently using a medication called mitotane
- People who had an unsuccessful surgical procedure for Cushing's syndrome within the last 6 weeks
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 833-827-9741
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of participants with treatment emergent adverse events (TEAEs); Proportion of participants with adrenal insufficiency; Proportion of participants with safety findings determined by laboratory testing; Assessment of the maximum observed plasma concentration of CRN04894; Assessment of the time to achieve maximum observed plasma concentration of CRN04894; Assessment of the plasma area under the curve of CRN04894
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.